Clinical Trials on Castrate-resistant Prostate Cancer (CRPC)

Total 5696 results

Rana McKay, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Metastatic Cancer | Castration-resistant Prostate Cancer

United States
Thomas Hope
Gateway for Cancer Research; Prostate Cancer Foundation; Conquer Cancer Foundation

Active, not recruiting

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
Emory University

Completed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Xencor, Inc.

Recruiting

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Bayer

Active, not recruiting

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone (RAPIT)

Castration-resistant Prostate Cancer

Taiwan
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Non-small Cell Lung Cancer (NSCLC) | Triple Negative Breast Cancer (TNBC) | NUT Midline Carcinoma (NMC) | Castration-resistant Prostate Cancer (CRPC)
Jonsson Comprehensive Cancer Center

Recruiting

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

Recurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer
University Hospital, Basel, Switzerland

Not yet recruiting

Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS)

Castration-resistant Prostate Cancer

Switzerland
Sidney Kimmel Comprehensive Cancer Center at Johns...
United States Department of Defense

Recruiting

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Castration Resistant Metastatic Prostate Cancer

United States
Noxopharm Limited

Terminated

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability | Hormone-Resistant Prostate Cancer | Castration Levels of Testosterone

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
Astellas Pharma Europe Ltd.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone (PRESIDE)

Metastatic Castration Resistant Prostate Cancer

Belgium, France, Spain, Austria, Czechia, Germany, Greece, Italy, Netherlands, Norway, Poland, Russian Federation, Sweden, Switzerland, Turkey, United Kingdom
Universitaire Ziekenhuizen KU Leuven

Active, not recruiting

Metastasis-directed Therapy in Castration-refractory Prostate Cancer (MEDCARE)

Castration-resistant Prostate Cancer

Belgium
Cardiff Oncology

Completed

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Dendreon

Completed

Sipuleucel-T Manufacturing Demonstration Study

Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of Prostate

Austria, France, Netherlands, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Orion Corporation, Orion Pharma

Completed

Safety and Pharmacokinetics of ODM-209 (STESIDES)

Advanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

Finland, France, Denmark
Hinova Pharmaceuticals Inc.

Recruiting

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

mCRPC

China
University of Wisconsin, Madison
Merck Sharp & Dohme LLC; Prostate Cancer Foundation; Madison Vaccines, Inc

Active, not recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer

United States
Lorenzo Livi

Unknown

Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) (ARTO)

Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Biochemically Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System; Prostate Cancer Foundation

Terminated

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Bayer

Terminated

A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels (CREDIT)

Bone Metastases | Metastatic Castration-resistant Prostate Cancer

China
Istituto Scientifico Romagnolo per lo Studio e...

Active, not recruiting

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) (LU-PSMA)

Metastatic Castration Resistant Prostate Cancer | 68Ga-PSMA PET/CT Positive

Italy
Roswell Park Cancer Institute
University of Pittsburgh

Completed

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of Prostate

United States
Cellbion Co., Ltd.

Recruiting

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Prostate Cancer | mCRPC

Korea, Republic of
VA Office of Research and Development
Merck Sharp & Dohme LLC

Recruiting

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP)

Metastatic Castration Resistant Prostate Cancer

United States
Amgen

Active, not recruiting

A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Metastatic Castration-resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
POINT Biopharma, a wholly owned subsidiary of Eli...
Eli Lilly and Company

Recruiting

[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)

Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer

Canada
Radboud University Medical Center

Completed

Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity (LEANDOC)

Breast Cancer | Metastatic Castration-resistant Prostate Carcinoma

Netherlands
pharmaand GmbH
Foundation Medicine

Active, not recruiting

A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

Metastatic Castration Resistant Prostate Cancer

United States, Canada, Spain, France, Australia, Ireland, Belgium, Denmark, United Kingdom, Germany, Israel, Italy
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Metastatic Castration Resistant Prostate Cancer

United States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
University of Washington
Bayer

Recruiting

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Unknown

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Bayer

Completed

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn (PRECISE)

Metastatic Castration-Resistant Prostate Cancer

Sweden
zr Pharma & GmbH

Completed

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP)

Metastatic Castration Resistant Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IV Prostate Cancer AJCC v7

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Regeneron Pharmaceuticals; Prostate Cancer Foundation

Withdrawn

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
Alliance Foundation Trials, LLC.
Patient-Centered Outcomes Research Institute

Completed

Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate

Netherlands, United States, United Kingdom
Pfizer

Recruiting

PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Small Cell Lung Cancer (SCLC) | Follicular Lymphoma (FL) | Castration Resistant Prostate Cancer (CRPC)

United States, Spain, Korea, Republic of, Poland, China, Bulgaria, Russian Federation, Japan
Roswell Park Cancer Institute

Withdrawn

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone | PSA...

United States
UNC Lineberger Comprehensive Cancer Center
Patient-Centered Outcomes Research Institute

Completed

North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)

Prostate Cancer | Cancer of the Prostate | Prostatic Cancer | Cancer of Prostate

United States

Clinical Trials on Castrate-resistant Prostate Cancer (CRPC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations